Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

Sep. 24, 2024 — Parkinson's disease, a debilitating nervous system disorder, is treated with medications that sometimes cause impaired decision-making and poor ... Some Diabetes Drugs Tied to ...

In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...

The following column was originally published on Feb. 25, 2022. Thanks to breakthroughs in medicine and nutrition in recent years, we are living longer than ever before. But this increase in life ...

In the United States, out-of-pocket (OOP) costs of brand-name medications for neurological ... and 45,909 with Parkinson’s ...

A large trial showed that semaglutide, sold as Ozempic for diabetes and as Wegovy for obesity, was better than any current ...

Subscribe to Here’s the Deal, our politics newsletter for analysis you won’t find anywhere else.

The amount of money people pay out-of-pocket for branded drugs to treat neurological diseases like multiple sclerosis (MS), ...

Amneal Pharmaceuticals Q3 sales rose 13% to $702.47 million, beating estimates. EPS hit $0.16, above consensus, driven by ...

Study hopes to inform the research agenda and help future research to focus on the questions that are most important to key stakeholders.